IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 240 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.39 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $93,834,000 | -45.9% | 11,700,000 | 0.0% | 1.25% | -38.2% |
Q1 2024 | $173,394,000 | +218.3% | 11,700,000 | +74.6% | 2.02% | +168.9% |
Q4 2023 | $54,471,000 | +78.7% | 6,700,000 | 0.0% | 0.75% | +58.3% |
Q3 2023 | $30,485,000 | -35.4% | 6,700,000 | 0.0% | 0.48% | -25.8% |
Q2 2023 | $47,168,000 | +10.0% | 6,700,000 | -4.6% | 0.64% | +0.6% |
Q1 2023 | $42,892,200 | -4.4% | 7,020,000 | 0.0% | 0.64% | -5.1% |
Q4 2022 | $44,857,800 | -48.1% | 7,020,000 | -22.2% | 0.67% | -58.0% |
Q3 2022 | $86,412,000 | -15.1% | 9,020,000 | -2.2% | 1.60% | -20.6% |
Q2 2022 | $101,789,000 | -33.0% | 9,220,000 | +1.0% | 2.01% | -27.5% |
Q1 2022 | $151,931,000 | -8.3% | 9,125,000 | +5.2% | 2.77% | -1.6% |
Q4 2021 | $165,606,000 | -21.6% | 8,675,000 | -5.2% | 2.82% | -15.0% |
Q3 2021 | $211,150,000 | -10.8% | 9,150,000 | +0.5% | 3.32% | -19.5% |
Q2 2021 | $236,782,000 | -6.5% | 9,100,000 | +13.8% | 4.12% | -5.8% |
Q1 2021 | $253,280,000 | -27.2% | 8,000,000 | +6.7% | 4.37% | -27.0% |
Q4 2020 | $348,000,000 | +10.9% | 7,500,000 | -21.4% | 5.99% | +34.4% |
Q3 2020 | $313,926,000 | +10.4% | 9,536,039 | -8.0% | 4.46% | -20.7% |
Q2 2020 | $284,411,000 | +4.2% | 10,361,039 | +1.0% | 5.62% | -38.9% |
Q1 2020 | $272,852,000 | +11.7% | 10,260,413 | +16.3% | 9.21% | +28.4% |
Q4 2019 | $244,305,000 | +26.6% | 8,826,039 | -16.7% | 7.17% | -10.9% |
Q3 2019 | $192,939,000 | -26.8% | 10,601,039 | -1.4% | 8.05% | -11.7% |
Q2 2019 | $263,653,000 | +163.3% | 10,752,585 | +2.1% | 9.11% | +110.4% |
Q1 2019 | $100,148,000 | +10.3% | 10,530,862 | +2.6% | 4.33% | -20.2% |
Q4 2018 | $90,810,000 | -6.8% | 10,261,039 | +18.5% | 5.43% | +21.3% |
Q3 2018 | $97,456,000 | -6.9% | 8,662,720 | +5.9% | 4.48% | +11.0% |
Q2 2018 | $104,675,000 | -23.3% | 8,177,720 | +1.2% | 4.03% | -38.2% |
Q1 2018 | $136,527,000 | +224.8% | 8,078,505 | +53.8% | 6.52% | +139.4% |
Q4 2017 | $42,028,000 | +29.1% | 5,253,450 | +25.0% | 2.72% | +7.9% |
Q3 2017 | $32,560,000 | +6.7% | 4,201,343 | +1.2% | 2.52% | -34.5% |
Q2 2017 | $30,512,000 | – | 4,151,343 | – | 3.85% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
MHR Fund Management | 19,997,103 | $90,986,819 | 11.15% |
MPM BioImpact LLC | 3,287,397 | $14,957,656 | 3.99% |
Perceptive Advisors | 11,962,938 | $54,431,367 | 1.82% |
CM Management, LLC | 200,000 | $910,000 | 0.97% |
Velan Capital Investment Management LP | 250,000 | $1,137,500 | 0.92% |
Opaleye Management Inc. | 610,000 | $2,775,500 | 0.90% |
Boxer Capital, LLC | 3,705,133 | $16,858,355 | 0.90% |
SECTORAL ASSET MANAGEMENT INC | 985,000 | $4,481,750 | 0.87% |
Parametrica Management Ltd | 95,400 | $434,070 | 0.73% |
683 Capital Management, LLC | 2,050,000 | $9,327,501 | 0.72% |